In ovarian cancer, FOXK2, as a highly expressed stemness-specific transcription factor, increased stemness features and tumour initiation capacity by directly activating the IRE1α-XBP1 pathway, while genetic or pharmacological blockade of this pathway inhibited ovarian CSCs [210]. This evidence concerns the gene ERN1 and ovarian carcinoma.